Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;41(3):656-63.
doi: 10.1093/schbul/sbu164. Epub 2014 Nov 24.

Antipsychotic treatment and mortality in schizophrenia

Minna Torniainen  1 , Ellenor Mittendorfer-Rutz  2 , Antti Tanskanen  2 , Charlotte Björkenstam  2 , Jaana Suvisaari  1 , Kristina Alexanderson  2 , Jari Tiihonen  3
Affiliations

Antipsychotic treatment and mortality in schizophrenia

Minna Torniainen et al. Schizophr Bull. 2015 May.

Erratum in

  • Erratum. Antipsychotic treatment and mortality in schizophrenia.
    Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Björkenstam C, Suvisaari J, Alexanderson K, Tiihonen J. Torniainen M, et al. Schizophr Bull. 2016 Mar;42(2):528. doi: 10.1093/schbul/sbv181. Epub 2016 Jan 26. Schizophr Bull. 2016. PMID: 26818883 Free PMC article. No abstract available.

Abstract

Background: It is generally believed that long-term use of antipsychotics increases mortality and, especially, the risk of cardiovascular death. However, there are no solid data to substantiate this view.

Methods: We identified all individuals in Sweden with schizophrenia diagnoses before year 2006 (N = 21 492), aged 17-65 years, and persons with first-episode schizophrenia during the follow-up 2006-2010 (N = 1230). Patient information was prospectively collected through nationwide registers. Total and cause-specific mortalities were calculated as a function of cumulative antipsychotic exposure from January 2006 to December 2010.

Results: Compared with age- and gender-matched controls from the general population (N = 214920), the highest overall mortality was observed among patients with no antipsychotic exposure (hazard ratio [HR] = 6.3, 95% CI: 5.5-7.3), ie, 0.0 defined daily dose (DDD)/day, followed by high exposure (>1.5 DDD/day) group (HR = 5.7, 5.2-6.2), low exposure (<0.5 DDD/day) group (HR = 4.1, 3.6-4.6), and moderate exposure (0.5-1.5 DDD/day) group (HR = 4.0, 3.7-4.4). High exposure (HR = 8.5, 7.3-9.8) and no exposure (HR = 7.6, 5.8-9.9) were associated with higher cardiovascular mortality than either low exposure (HR = 4.7, 3.7-6.0) or moderate exposure (HR = 5.6, 4.8-6.6). The highest excess overall mortality was observed among first-episode patients with no antipsychotic use (HR = 9.9, 5.9-16.6).

Conclusions: Among patients with schizophrenia, the cumulative antipsychotic exposure displays a U-shaped curve for overall mortality, revealing the highest risk of death among those patients with no antipsychotic use. These results indicate that both excess overall and cardiovascular mortality in schizophrenia is attributable to other factors than antipsychotic treatment when used in adequate dosages.

Keywords: antipsychotic; mortality; schizophrenia.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
(a) Overall mortality as hazard ratios in the chronic patient population (N = 21492) compared with mortality in the control sample. (b) Overall mortality as hazard ratios in first-episode patients (N = 1230) compared with mortality in the control sample.
Fig. 2.
Fig. 2.
Mortality expressed as hazard ratios due to specific causes in patients with schizophrenia compared with the control sample.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620–627. - PubMed
    1. Laursen TM, Wahlbeck K, Hällgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013;8:e67133. - PMC - PubMed
    1. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–235. - PMC - PubMed
    1. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113:1–11. - PubMed
    1. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324–333. - PubMed

Publication types

Substances